Vaccine Offers Current Defense Against Equine Influenza
Zoetis partners with Gluck Center to confirm relevant disease protection against new strains
FLORHAM PARK, N.J., Sept. 9, 2014 — Zoetis has partnered with the renowned Gluck Equine Research Center at the University of Kentucky to show that FLUVAC INNOVATOR®, the first equine influenza virus (EIV) vaccine, can provide a demonstrated cross-reactive immune response against emerging EIV strains.
Their most recent study demonstrated an immune response against Richmond 07.1 Although Richmond 07 is not circulating in the United States, it might be a threat to horses with international exposure. Zoetis put FLUVAC INNOVATOR to the test, and it succeeded.
To help ensure vaccines offer current protection, the World Organisation for Animal Health (OIE) encourages vaccine manufacturers to work with laboratories, such as the Gluck Center, that can test for reactivity against circulating strains.2
In fact, the FLUVAC INNOVATOR line of vaccines sets the standard for equine influenza vaccine protection. With test studies against six EIV strains since 2002, Zoetis continues its legacy of evaluating the FLUVAC INNOVATOR line of vaccines to help ensure the most relevant protection.1,3-6
This commitment to providing an immunologically current EIV vaccine has made FLUVAC INNOVATOR the most trusted EIV line of vaccines, as well as the market leader.7
After all, the best way to help protect horses against EIV is to vaccinate before exposure to this highly contagious respiratory disease.8 And that’s why horse owners can depend on the FLUVAC INNOVATOR vaccine line, because it helps offer demonstrated protection against EIV and is backed by the Zoetis commitment to continuously monitor and evaluate the efficacy and safety of its products.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2013, the company generated annual revenues of $4.6 billion. With approximately 9,800 employees worldwide at the beginning of 2014, Zoetis has a local presence in approximately 70 countries, including 27 manufacturing facilities in 10 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information, visit www.zoetisUS.com.
Zoetis is the proud sponsor, with the Smithsonian Institution Traveling Exhibition Service, the American Veterinary Medical Association and the American Veterinary Medical Foundation, of the mobile educational exhibit Animal Connections: Our Journey Together. Families visiting the exhibit will explore the vast bonds between people and animals and learn about the important role veterinarians play in protecting animal and human health.
For further information, Contact:
1 Data on file, Study Report No. 14OREQBIO-1, Zoetis Inc.
2 OIE expert surveillance panel on equine influenza composition. OIE Bulletin 2010;2:44-45.
3 Data on file, Study Report No. 671-02-001R, Zoetis Inc.
4 Data on file, Study Report No. 671-08-004.R, Zoetis Inc.
5 Data on file, Study Report No. 766-09-002.R, Zoetis Inc.
6 Data on file, Study Report No. 10OREQBIO-01, Zoetis Inc.
7 Data on file, MDI Sales Data from 2004-2013, Zoetis Inc.
8 TheHorse.com. Equine Influenza Vaccine Protocols: Boosters are best. Available at: http://www.thehorse.com/articles/25042/equine-influenza-vaccine-protocols-boosters-are-best. Accessed July 9, 2014.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States